

```
=> b reg
FILE 'REGISTRY' ENTERED AT 12:42:24 ON 18 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8
DICTIONARY FILE UPDATES: 16 NOV 2009 HIGHEST RN 1192511-54-8
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d que sta 17

1.4 STR



```
VAR G1=C/N
VAR G2=O/N/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L7 415 SEA FILE=REGISTRY SSS FUL L4

```
100.0% PROCESSED      9030 ITERATIONS      415 ANSWERS
SEARCH TIME: 00.00.01
```

```
=> b zcap
FILE 'ZCAPLUS' ENTERED AT 12:42:39 ON 18 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2009 VOL 151 ISS 21
FILE LAST UPDATED: 17 Nov 2009 (20091117/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> d bib abs hitrn fhitr 110 tot

L10 ANSWER 1 OF 1 SCAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:570902 SCAPLUS
DN 143:97403

TI Pyrido- and pyrimidopyrimidine derivatives as antiproliferative agents
IN Freyne, Eddy Jean Edgard; Willems, Marc; Storch, Pierre Henri; Poncolet,
Virginie Sophie; Van Emelen, Kristof; Buijsters, Peter Jacobus Johannes
Antonius; Embrechts, Werner Constant Johan; Perera, Timothy Pietro Suren
Janssen Pharmaceutica N.V., Belg.


PA PCT Int. Appl., 64 pp.
GO CODEN: PIXXD2

DT Patent

LA English

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005058913	A1	20050630	2004WO-EP0053501	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TE, UA, US, VE, VC, VN, YU, ZA, ZM, ZW				
PW: BW, CH, GM, KE, LG, MW, NE, NA, SD, SL, SE, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GH, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004298448	A1	20050630	2004AU-000298448	20041215
CA-----2549869	A1	20050630	2004CA-002549869	20041215
EP-----1697384	A1	20060906	2004EP-000804852	20041215
EP-----1697384	B1	20080402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
BR--2004017534	A	20070327	2004BR-000017534	20041215
JP--2007514712	T	20070607	2006JP-000544440	20041215
AT-----391129	T	20080415	2004AT-000804852	20041215
ES-----2305887	T3	20081101	2004ES-000804852	20041215
US--20070078132	A1	20070405	2006US-000596512	20060615
ZA--2006004972	A	20081231	2006ZA-000004972	20060615
IN--200603474	A	20070831	2006IN-000003474	20060616
MX--2006007017	A	20060831	2006MX-000007017	20060619
RP--2006126716	A	20061108	2006RP-000714323	20060714
NO--2006003323	A	20060718	2006NO-000003323	20060718
PRAI 2003WO-EP0051058	A	20031218		
2003WO-EP0051062	A	20031218		
2004WO-EP0053501	W	20041215		
OS CASREACT 143:97403; MARPAT 143:97403				
GI				



I

AB The present invention concerns pyrido- and pyrimidopyrimidine macrolide derivs. One example compound prepared was I. Reactions are given for preparation of a number of intermediates and other derivs. similar to I. Pharmacol. data include in vitro inhibition of EGF receptors and serum starved proliferation assay on ovarian carcinoma SKOV3 cells.

II 855995-90-3P 855995-93-6P

L10 ANSWER 1 OF 1 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent)

II (pyrido- and pyrimidopyrimidine derivs. prepn. as antiproliferative agents)

855995-91-4P 855995-92-5P 855995-94-7P

855995-95-8P 855995-96-9P 855995-97-0P

855995-98-1P 855995-99-2P 855995-00-8P

855996-01-9P 855996-02-0P 855996-03-1P

855996-04-2P 855996-05-3P 855996-06-4P

855996-07-5P 855996-08-6P 855996-09-7P

855996-10-0P 855996-11-1P 855996-12-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrido- and pyrimidopyrimidine derivs. preparation as antiproliferative agents)

II 855995-90-3P


RL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PACT (Reactant or reagent)

(pyrido- and pyrimidopyrimidine derivs. preparation as antiproliferative agents)

RN 855995-90-3 SCAPLUS

CN 4,4-Ethenopyrimido[4,5-b][1,4,6,11]benzotetraazacyclotetradecine, 16-chloro-15-fluoro-1,5,8,11,12,13-hexahydro-12-methyl-, (9E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l15 tot


L15 ANSWER 1 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN
 RN 2009:885621 SCAPLUS
 DN 151:189956
 TI Compositions and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor
 IN Adrian, Francisco; Dierks, Christine; Gray, Nathanael S.; Warmuth, Markus
 PA IRM LLC, Bermuda
 SO PCT Int. Appl., 56pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2009091476	A1	20090723	2008MO-US0087344	20081218
W: AB, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SN, SV, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI 2008US-00021006P	P	20080114		

OS MARPAT 151:189956
 AB This invention provides a combination of ATP-competitive BCR-ABL inhibitor and a non-ATP competitive BCR-ABL inhibitor, such as GNF-2 and imatinib or GNF-5 and nilotinib. The combination of the present invention may be used for treating cancers known to be associated with BCR-ABL.

IT **807640-87-5**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)

RN **807640-87-5** SCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN
 RN 2008:530104 SCAPLUS
 DN 148:509909
 TI Macrocyclic quinazoline derivative VEGFR3 VEGF receptor inhibitors
 IN Perera, Timothy Pietro Suren; Versels, Matthias Luc A.; Page, Martin John
 PA Janssen Pharmaceutica NV, Belg.
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2008049902	A2	20080502	2007MO-EP0061499	20071025
WO--2008049902	A3	20081002		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US-20080219975	A1	20080911	2007US-000875388	20071019
AU--2007310843	A1	20080502	2007AU-000310843	20071025
CA--2664148	A1	20080502	2007CA-002664148	20071025
EP-----207845	A2	20090715	2007EP-000821862	20071025
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR--2009089849	A	20090824	2009KR-000709081	20071025
MX--2009004436	A	20090522	2009MX-00004436	20090424
IN--200900818	A	20090703	2009IN-00000818	20090427
CN--101528235	A	20090909	2007CN-000039993	20090427
NO--200902045	A	20090626	2009NO-000002045	20090526

PRAI 2008EP-000121056
 2006US-00863198P
 2007US-00976210P
 2007MO-EP0061499
 W 20071025


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 148:509909
 AB The invention discloses the use of some of the macrocyclic quinazoline derivs. described in PCT publication WO2004/105765 as inhibitors of VEGFR3-mediated biol. activities, especially those activities which are mediated by VEGFR3 ligands VEGF-C and/or VEGF-D. Compound preparation is described. The comps. are useful e.g. in the treatment of cancer.


IT **807640-68-2P** **807640-87-5P** **807642-12-2P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (macrocyclic quinazoline derivative VEGFR3 VEGF receptor inhibitors, and use with other agents)

RN **807640-68-2** SCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,13]benzodioxazacyclopentadecine, 15-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)


L15 ANSWER 2 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN (Continued)



RN **807640-87-5** SCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN **807642-12-2** SCAPLUS
 CN 12H-4,6-Etheno-13,17-methanopyrimido[4,5-b][6,1,10,16]benzoxatriazacyclononadecin-12-one, 21-chloro-1,8,9,10,11,13,14,15,16,18-decahydro-25-methoxy- (CA INDEX NAME)




IT **807640-68-2D**, salts **807640-87-5D**, salts **807642-12-2D**, salts **807642-13-3** **807642-13-3D**
 salts
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrocyclic quinazoline derivative VEGFR3 VEGF receptor inhibitors, and use with other agents)

RN **807640-68-2** SCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,13]benzodioxazacyclopentadecine, 15-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)


L15 ANSWER 2 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN (Continued)




RN **807640-87-5** SCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)



RN **807642-12-2** SCAPLUS
 CN 12H-4,6-Etheno-13,17-methanopyrimido[4,5-b][6,1,10,16]benzoxatriazacyclononadecin-12-one, 21-chloro-1,8,9,10,11,13,14,15,16,18-decahydro-25-methoxy- (CA INDEX NAME)




RN **807642-13-3** SCAPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl- (CA INDEX NAME)



L15 ANSWER 2 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 807642-13-3 ZCAPLUS

CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl- (CA INDEX NAME)



IT 1021691-20-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(macrocyclic quinazoline derivative VEGFR3 VEGF receptor inhibitors, and use with other agents)

RN 1021691-20-2 ZCAPLUS

CN 4,6-Etheno-12H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:529663 ZCAPLUS

DN 148:509908

TI Use of a macrocyclic quinazoline derivative MT kinase inhibitor for

treating or preventing brain cancer

IN Perera, Timothy Pietro Suren; Page, Martin John; Janicot, Michel Marie

Francois; Freyne, Eddy Jean Edgard

PA Janssen Pharmaceutica NV, Belg.

SO PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO--2008049901 A1 20080502 2007MO-EP0061498 20071025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BE, CA,

CH, CN, CO, CR, CU, CE, DE, DK, DM, DO, DE, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KM, KN, KP, KR, KS, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL,

PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,

TR, TT, TS, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

FW: AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

GH, GM, KE, LS, MW, ME, NA, SD, SL, SS, TZ, UG, ZM, ZW, AM, AE,

BY, KG, KE, MD, RU, TJ, TM

US--20080153933 A1 20080626 2007US--000875350 20071019

AU--2007310842 A1 20080502 2007AU--000310842 20071025

CA-----2664145 A1 20080502 2007CA--002664145 20071025

EP-----2077843 A1 20090715 2007EP--00821861 20071025

R: AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,

AL, BA, HR, MK, RS

KR--2009091119 A 20090826 2009KR--000709076 20071025

MX--2009004437 A 20090511 2009MX--000004437 20090424

CN---101528233 A 20090909 2007CN--080039989 20090427

NO--2009002046 A 20090701 2009NO--000002046 20090526

PRAI 2006EP--000123058 A 20061027

2006US--00863162P P 20061027

2007US--00976188P P 20070928

2007MO--EP0061498 W 20071025

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L5US DISPLAY FORMAT

AB The invention is concerned with the finding that the macrocyclic

quinazoline derivative 4,6-ethanediyldene-pyrimido[4,5-

b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described

as compound 22 in PCT publication WO2004/105765, is useful in the manufacture of

a medicament for the treatment of a prevention of a primary brain cancer or

brain metastasis. The invention accordingly provides methods for

treating, preventing, delaying or mitigating brain cancer, or for

preventing or slowing proliferation of cells of brain origin. Compound

preparation is described.

IT 807640-87-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(macrocyclic quinazoline derivative MT kinase inhibitor for treatment or

prevention of brain cancer)


RN 807640-87-5 ZCAPLUS

CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine,

17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX

NAME)

L15 ANSWER 3 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 1021686-80-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(macrocyclic quinazoline derivative MT kinase inhibitor for treatment or


prevention of brain cancer)

RN 1021686-80-5 ZCAPLUS

CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine,

17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-,

hydrobromide (1:2) (CA INDEX NAME)



● 2 HBx

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:529205 ZCAPLUS

DN 148:509905

TI Use of MKT1 1 for treating or preventing bone cancer

IN Perera, Timothy Pietro Suren; Janicot, Michel Marie Francois; Meert, Theo

Franz; Freyne, Eddy Jean Edgard

PA Janssen Pharmaceutica NV, Belg.

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO--2008049904 A2 20080502 2007MO--EP0061501 20071025

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BE, CA,

CH, CN, CO, CR, CU, CE, DE, DK, DM, DO, DE, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KM, KN, KP, KR, KS, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL,

PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,

TR, TT, TS, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

FW: AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,

GH, GM, KE, LS, MW, ME, NA, SD, SL, SS, TZ, UG, ZM, ZW, AM, AE,

BY, KG, KE, MD, RU, TJ, TM, AP, EA, EP, OA

US--20080213275 A1 20080904 2007US--000875429 20071019

AU--2007310845 A1 20080502 2007AU--000310845 20071025

CA-----2664165 A1 20080502 2007CA--002664165 20071025

KR--2009086977 A 20090814 2009KR--000709079 20071025

EP-----2101782 A2 20090923 2007EP--00821864 20071025

R: AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,

AL, BA, HR, MK, RS

MX--2009004438 A 20090511 2009MX--000004438 20090424

CN---101528234 A 20090909 2007CN--080039984 20090424

NO--2009002059 A 20090629 2009NO--000002059 20090527

PRAI 2006EP--000123060 A 20061027

2006US--00863167P P 20061027

2007US--00976188P P 20070928

2007MO--EP0061501 W 20071025

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN L5US DISPLAY FORMAT

AB The invention is concerned with the finding that the macrocyclic

quinazoline derivative 4,6-ethanediyldene-pyrimido[4,5-

b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,

14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT

publication WO2004/105765, is useful in the manufacture of a medicament for the

treatment or prevention of bone cancers and methods for killing bone

cancer cells, including osteosarcomas, chondrosarcomas, myeloma bone

disease and osteolytic bone metastases from other primary sites. The

invention provides methods for treating, preventing, delaying or

mitigating bone cancer, or for preventing and treating of bone loss

associated with cancer metastases. Compound preparation is described.

IT 807640-87-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(MKT1 1 for treating or preventing bone cancer, and use with other

agents)


RN 807640-87-5 ZCAPLUS

CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine,


17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX

NAME)

L15 ANSWER 4 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN (Continued)



IT **1021686-80-5**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MKTI 1 for treating or preventing bone cancer, and use with other agents)
 RN 1021686-80-5 SCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, hydrobromide (1:2) (CA INDEX NAME)




● 2 HBr

L15 ANSWER 5 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN (Continued)

L15 ANSWER 5 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN
 AN 2008:528119 SCAPLUS
 DN 148:510725
 IT Construction and application of peptide microarray for analyzing pharmacological profiles of kinase inhibitors
 IN Versele, Matthias Luc Aline; Perera, Timothy Pietro Suren; Tallon, Willem Jan-Paul Edmond
 PA Janssen Pharmaceutica N. V., Belg.
 SO PCT Int. Appl., 68pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2008049930	A2	20080502	2007MO-EP0061614	20071029
WO--2008049930	A3	20080925		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DO, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MD, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BF, BG, KE, MD, RU, TJ, TM, AP, EA, EP, OA			
AU--2007310787	A1	20080502	2007AU-000310787	20071029
CA--2664114	A1	20080502	2007CA-002664114	20071029
EP--2089710	A2	20090819	2007EP-000821970	20071029
R:	AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRAI 2006EP-000121106	A	20061027		
2007MO-EP0061614	W	20071029		

AB The invention relates to a method of construction of peptide microarray for analyzing pharmacol. profiles of kinase inhibitors. The present invention is concerned with method for pharmacol. profiling compds. using an array of substrates, in particular kinase substrates, immobilized on a porous matrix. This method was found particular useful in the prediction of drug response, i.e. to enable the distinction between responders and non-responders in the treatment of cells, tissues, organs or warm-blooded animals with the compound to be tested, and in compound differentiation.
 IT **807640-87-5**
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (construction and application of peptide microarray for analyzing pharmacol. profiles of kinase inhibitors)
 RN 807640-87-5 SCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN (Continued)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS ON SIN
 AN 2008:72101 SCAPLUS
 DN 148:144796
 IT Preparation of quinazoline derivatives as antitumor agents
 IN Papanikos, Alexandra; Freyne, Eddy Jean Edgard; Ten Holte, Peter; Willems, Marc; Embrechts, Werner Constant Johan; Mevellec, Laurence Anne; Storck, Pierre Henri
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2008006884	A2	20080117	2007MO-EP0057200	20070712
WO--2008006884	A3	20080306		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DO, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MD, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BF, BG, KE, MD, RU, TJ, TM, AP, EA, EP, OA			
AU--2007274284	A1	20080117	2007AU-000274284	20070712
CA--2654582	A1	20080117	2007CA-002654582	20070712
EP--2044084	A2	20090408	2007EP-000787471	20070712
R:	AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
MX--2009000456	A	20090127	2009MX-00000456	20090112
CN--101490060	A	20090722	2007CN-080026483	20090112
PRAI 2006EP-000117185	A	20060719		
2007MO-EP0057200	W	20070712		
OS MARPAT 148:144796				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = alkyl, alkyloxyalkyl, substituted alkylaminoalkyl, etc.; X1 = O, O-alkyl, or (un)substituted aminoalkyl; X2 = bond, O, alkyl, etc.; R1 = H, CN, halo, OH, etc.; R2 = H, CN, halo, alkenyl, etc.; R3 = OH or (un)substituted alkyloxy], and their pharmaceutically acceptable salts, were prepared and disclosed as antitumor agents. Thus, e.g., II was prepared in a multistep synthesis involving chlorination of III followed by deacetylation and intramol. cyclization. I were evaluated as inhibitors of c-SRC and Fyn kinases, e.g., II possessed pIC50 values of 6.69 in the Fyn kinase assay (c-SRC not determined).

IT **1001431-91-9P** **1001432-00-3P**
 RL: PAC (Pharmacological activity); PRPH (Proprietary); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazoline derivs. as antitumor agents)


RN 1001431-91-9 SCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecine-10(11H)-carboxylic acid, 23-(3-bromopropoxy)-6,8,9,12,13,21-hexahydro-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-00-3 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 23-(3-bromopropoxy)-6,7,8,9,10,11,12,13,21-octahydro-7,8-dimethyl-, (8S)-(CA INDEX NAME)

Absolute stereochemistry.




IT 1001433-57-3P 1001433-58-4P 1001433-59-5P
 1001433-60-8P 1001433-61-9P
 RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline derivs. as antitumor agents)
 RN 1001433-57-3 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl- (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001433-58-4 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid, 4-bromo-6,7,8,9,10,11,12,20-hexahydro-22-[3-(4-methyl-1-piperazinyl)propoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

RN 1001433-59-5 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 1001433-60-8 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-22-(3-chloropropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001433-61-9 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,9,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, (8S)-(CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




IT 1001431-79-3P 1001431-80-6P 1001431-82-8P
 1001431-83-9P 1001431-84-0P 1001431-85-1P
 1001431-86-2P 1001431-88-4P 1001431-89-5P
 1001431-92-0P 1001431-93-1P 1001431-94-2P
 1001431-96-3P 1001431-97-5P 1001432-02-5P
 1001432-04-7P 1001432-06-9P 1001432-07-0P
 1001432-09-2P 1001432-11-6P 1001432-13-8P
 1001432-15-0P 1001432-17-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazoline derivs. as antitumor agents)
 RN 1001431-79-3 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid, 6,7,8,9,10,11,12,20-hexahydro-22-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001431-80-6 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-methoxy- (CA INDEX NAME)


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001431-82-8 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl- (CA INDEX NAME)




RN 1001431-83-9 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-22-ol, 6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001431-84-0 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[(2S)-2-oxiranylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001431-89-5 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-23-hydroxy-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001431-92-0 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-7-methyl-22-[3-(4-methyl-1-piperazinyl)propoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1001431-93-1 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-23-[2-(2-methoxyethoxy)ethoxy]-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001431-85-1 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7-methyl-10-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 1001431-86-2 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7-methyl- (CA INDEX NAME)




RN 1001431-88-4 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-23-ol, 6,8,9,10,11,12,13,21-octahydro-7-methyl- (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001431-94-2 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-23-[3-[(2-hydroxyethyl)methylamino]propoxy]-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1001431-95-3 SCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001431-97-5 SCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-02-5 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-morpholinyl)propoxy]-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 1001432-04-7 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-06-9 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-7(8H)-carboxylic acid, 4-bromo-6,9,10,11,12,20-hexahydro-22-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001432-07-0 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 22-(3-bromopropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)



RN 1001432-09-2 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecine-10(11H)-carboxylic acid, 6,8,9,12,13,21-hexahydro-7-methyl-23-[3-(4-(methylsulfonyl)-1-

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)
 piperidinyl)propoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1001432-11-6 ZCAPLUS
 CN Ethanol, 2-[methyl[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl]amino]- (CA INDEX NAME)




RN 1001432-13-8 ZCAPLUS
 CN Carbanic acid, N-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-15-0 ZCAPLUS
 CN 1-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]- (CA INDEX NAME)



RN 1001432-17-2 ZCAPLUS
 CN Propanamide, N-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl]-3-(methylsulfonyl)- (CA INDEX NAME)




IT 1001431-81-7P 1001431-87-3P 1001431-90-8P
 1001431-96-4P 1001431-98-6P 1001432-19-4P
 1001432-21-8P 1001432-23-0P 1001432-25-2P
 1001432-27-4P 1001432-29-6P 1001432-30-9P
 1001432-32-1P 1001432-34-3P 1001432-36-5P
 1001432-38-7P 1001432-40-1P 1001432-42-3P
 1001432-44-5P 1001432-46-7P 1001432-48-9P
 1001432-50-3P 1001432-52-5P 1001432-54-7P
 1001432-55-8P 1001432-56-9P 1001432-57-0P
 1001432-58-1P 1001432-59-2P 1001432-60-5P
 1001432-61-6P 1001432-62-7P 1001432-63-8P
 1001432-64-9P 1001432-65-0P 1001432-66-1P

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

1001432-67-2P 1001432-68-3P 1001432-69-4P
 1001432-70-7P 1001432-71-8P 1001432-72-9P
 1001432-73-0P 1001432-74-1P 1001432-75-2P
 1001432-76-3P 1001432-77-4P 1001432-78-5P
 1001432-79-6P 1001432-80-9P 1001432-81-0P
 1001432-82-1P 1001432-83-2P 1001432-84-3P
 1001432-85-4P 1001432-86-5P 1001432-87-6P
 1001432-88-7P 1001432-89-8P 1001432-90-1P
 1001432-91-2P 1001432-92-3P 1001432-93-4P
 1001432-94-5P 1001432-95-6P 1001432-96-7P
 1001432-97-8P 1001432-98-9P 1001432-99-0P
 1001433-00-6P 1001433-01-7P 1001433-02-8P
 1001433-03-9P 1001433-04-0P 1001433-05-1P
 1001433-06-2P 1001433-07-3P 1001433-08-4P
 1001433-09-5P 1001433-10-6P 1001433-11-7P
 1001433-12-0P 1001433-13-1P 1001433-14-2P
 1001433-15-3P 1001433-16-4P 1001433-17-5P
 1001433-18-6P 1001433-19-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


RN 1001431-81-7 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,7,8,9,10,11,12,13,21-octahydro-23-methoxy-, hydrobromide (1:2) (CA INDEX NAME)



● 2 HBr


RN 1001431-87-3 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,7,8,9,10,11,12,13,21-octahydro-23-methoxy-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 3 HCl


RN 1001431-90-8 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-10(11H)-carboxylic acid, 23-[[[(1,1-dimethylethoxy)carbonyl]oxyl]-6,8,9,12,13,21-hexahydro-7-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1001431-96-4 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 2 HCl

RN 1001431-98-6 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 1001432-19-4 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxatriazacyclohexadecine-7(8H)-carboxylic acid, 6,9,10,11,12,20-hexahydro-22-methoxy-4-[(6-methyl-3-pyridinyl)oxyl]-, phenylmethyl ester (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-21-8 ZCAPLUS
 CN 1-Piperidineethanol, α-[[[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxatriazacyclohexadecine-22-yl)oxyl]methyl]-, hydrochloride (1:3), (αS)- (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 1001432-23-0 ZCAPLUS
 CN 4-Thiomorpholinethanol, α-[[[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxatriazacyclohexadecine-22-yl)oxyl]methyl]-, 1,1-dioxide, hydrochloride (1:3), (αS)- (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1001432-25-2 ZCAPLUS
 CN 4-(Trifluoromethyl)ethanol, 2-[[[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]methyl]-, 1,1-dioxide, hydrochloride (1:3), (aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001432-27-4 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RN 1001432-29-6 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[(2S)-2-hydroxy-3-(4-hydroxy-1-piperidinyl)propoxy]-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-30-9 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-(2-methoxyethoxy)-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 1001432-32-1 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-[2-(2-methoxyethoxy)ethoxy]-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)




RN 1001432-34-3 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 22-(3,3-diethoxypropoxy)-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001432-36-5 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-22-(2-methoxyethoxy)-, hydrochloride (1:2)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RN 1001432-38-7 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (1:5) (CA INDEX NAME)




RN 1001432-40-1 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-[3-(4-morpholinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-42-3 ZCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 1001432-44-5 ZCAPLUS
CN Ethanol, 2-[methyl-3-[(6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-23-yl)oxy]propyl]amino]-, hydrochloride (1:4) (CA INDEX NAME)


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-50-3 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 23-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-46-7 ZCAPLUS
CN 1-Propanamine, N-(2-methoxyethyl)-3-[(6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-23-yl)oxy]-, hydrochloride (1:4) (CA INDEX NAME)



● 4 HCl

RN 1001432-48-9 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-morpholinyl)propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


PAGE 2-A



RN 1001432-52-5 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 23-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 1001432-54-7 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[3-[(2-methoxyethyl)amino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 3 HCl

RN 1001432-55-8 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[3-[(2-hydroxyethyl)amino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 1001432-56-9 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[3-[(2-hydroxyethyl)methylamino]propoxy]-7,8-dimethyl-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 3 HCl

RN 1001432-57-0 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)ethoxy]-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 1001432-58-1 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-[2-(2-methoxyethoxy)-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 2 HCl


RN 1001432-59-2 SCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[(2S)-2-oxiranylmethoxy]-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001432-60-5 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




● 2 HCl

RN 1001432-61-6 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 4-bromo-6,7,8,9,10,11,12,20-octahydro- (CA INDEX NAME)




RN 1001432-62-7 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 6,7,8,9,10,11,12,20-octahydro- (CA INDEX NAME)




RN 1001432-63-8 SCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-ol, 6,7,8,9,10,11,12,20-octahydro-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




● 2 HCl

RN 1001432-64-9 SCAPLUS
CN 13,3]Dioxolo[4,5-o]quinazolino[4,5-bc][5,1,10]benzoxadiazacyclotridecine, 6,7,8,9,10,16-hexahydro-2-methoxy- (CA INDEX NAME)




RN 1001432-65-0 SCAPLUS
CN 13,3]Dioxolo[4,5-p]quinazolino[4,5-bc][5,1,11]benzoxadiazacyclotetradecine, 5,6,7,8,9,10,11,17-octahydro-2-methoxy- (CA INDEX NAME)




RN 1001432-66-1 SCAPLUS
CN 4,6-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-2-methoxy- (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




● 2 HCl

RN 1001432-70-7 SCAPLUS
CN 4,6-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-21-methoxy-12-methyl- (CA INDEX NAME)




RN 1001432-71-8 SCAPLUS
CN 4,6-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 8,9,10,11,12,13,14,20-octahydro-21-methoxy-12-methyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 1001432-72-9 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-23-methoxy-7,10-dimethyl- (CA INDEX NAME)


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001432-67-2 SCAPLUS
CN 4,6-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine-12(13H)-carboxylic acid, 8,9,10,11,14,20-hexahydro-21-methoxy-, phenylmethyl ester (CA INDEX NAME)




RN 1001432-68-3 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-22-ol, 4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl- (CA INDEX NAME)




RN 1001432-69-4 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-73-0 SCAPLUS
CN 15,17-Etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 7,8,9,10,11,12,13,21-octahydro-23-methoxy-7,10-dimethyl-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 1001432-74-1 SCAPLUS
CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-23-ol, 6,8,9,10,11,12,13,21-octahydro-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 1001432-75-2 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ECAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-76-3 ECAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(4-morpholinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)




RN 1001432-77-4 ECAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-piperidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ECAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-78-5 ECAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-pyrrolidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)




RN 1001432-79-6 ECAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(1-pyrrolidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ECAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




Absolute stereochemistry.

PAGE 1-A




L15 ANSWER 6 OF 7 ECAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001432-81-0 ECAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-9-one, 6,7,8,10,11,13,14,15,21-octahydro-3,14-dimethyl-23-[4-[2-(methylsulfonyl)ethyl]-1-piperidinyl]propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 1001432-82-1 ECAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-9-one, 6,7,8,10,11,13,14,15,21-octahydro-3,14-dimethyl-23-[4-[2-(methylsulfonyl)ethyl]-1-piperidinyl]propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-(methylsulfonyl)-1-piperidinyl)propoxy]-, hydrochloride (1:3), (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



● 3 HCl


RN 1001432-83-2 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 3 HCl


RN 1001432-84-3 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 22-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-6,7,8,9,10,11,12,20-octahydro-7-methyl-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 1001432-85-4 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-[3-(1-pyrrolidinyl)propoxy]-, hydrochloride (1:3) (CA INDEX NAME)


L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 3 HCl


RN 1001432-86-5 SCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)

PAGE 1-A



L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 2-A




● 4 HCl

RN 1001432-87-6 SCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-methyl-1-piperazinyl)propoxy]-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 1001432-88-7 SCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-(4-methyl-1-piperazinyl)propoxy]-, (8S)- (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)
piperazinylpropoxyl-, hydrochloride (1:4), (8S)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 2-A


● 4 HCl

RN 1001432-89-8 SCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecine-9-one, 6,7,8,10,11,12,13,21-octahydro-7,8-dimethyl-23-[3-[4-[3-(methylsulfonyl)-1-oxopropyl]-1-piperaziny]ethoxy]-, (8S)- (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

PAGE 1-A



PAGE 2-A




RN 1001432-90-1 SCAPLUS
CN Acetamide, N-[2-[4-[3-[(7,8,9,10,11,12,13,21-octahydro-7,8-dimethyl-9-oxo-15,17-etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecine-23-yl)oxy]propyl]-1-piperaziny]ethyl]-, hydrochloride (1:4) (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

PAGE 1-A



PAGE 2-A




● 4 HCl

RN 1001432-91-2 SCAPLUS
CN Acetamide, N-[2-[4-[3-[(7,8,9,10,11,12,13,21-octahydro-7,8-dimethyl-9-oxo-15,17-etheno-6H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecine-23-yl)oxy]propyl]-1-piperaziny]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


PAGE 1-A



PAGE 2-A




RN 1001432-92-3 SCAPLUS
CN 1-Piperazineethanol, 4-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclononadecine-22-yl)oxy]propyl]- (CA INDEX NAME)




RN 1001432-93-4 SCAPLUS
CN 1-Propanone, 1-[4-[2-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy)ethyl]-1-piperidinyl]-3-(methylsulfonyl)-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 1001432-94-5 ZCAPLUS
 CN 1-Piperazineethanol, 4-[(3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)methylamino]-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



● 4 HCl

RN 1001432-96-7 ZCAPLUS
 CN Ethanol, 2-[(3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)methylamino]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 1001432-97-8 ZCAPLUS
 CN 1-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]-N-[2-(methylsulfonyl)ethyl]-, hydrochloride (1:3) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 1001432-95-6 ZCAPLUS
 CN 15,17-Etheno-7H-[1,2]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-(3-[(4-(methylsulfonyl)-1-piperidinyl)propoxy]-, hydrochloride (1:4) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




● 3 HCl

RN 1001432-98-9 ZCAPLUS
 CN Ethanol, 2-[(3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)amino]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 1001432-99-0 ZCAPLUS
 CN 1-Propanamine, 3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]-N-(2-methoxyethyl)-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 1001433-00-6 ZCAPLUS
 CN Ethanol, 2-[(3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-b]pyrimido[4,5-

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)
b) [6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl]amino]- (CA INDEX NAME)




RN 1001433-01-7 ZCAPLUS
CN Ethanol, 2-[(3-[(4-bromo-6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl)methylamino]- (CA INDEX NAME)




RN 1001433-02-8 ZCAPLUS
CN Propanamide, N-[3-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-22-yl)oxy]propyl]-3-(methylsulfonyl)-, hydrochloride (1:2) (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001433-05-1 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8-dimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001433-06-2 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



● 2 HCl

RN 1001433-03-9 ZCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin, 6,7,8,9,10,11,12,20-octahydro-22-methoxy-4-[(6-methyl-3-pyridinyl)oxy]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 1001433-04-0 ZCAPLUS
CN 14,16-Etheno-1,3-dioxolo[4,5-q]pyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-4-carbonitrile, 6,7,8,9,10,11,12,20-octahydro-22-methoxy-7-methyl-, (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


RN 1001433-07-3 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 4-chloro-6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1001433-08-4 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, hydrochloride (1:2), (8S)- (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl


RN 1001433-09-5 ZCAPLUS
CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,10-trimethyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001433-10-8 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,8-trimethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 1001433-11-9 ZCAPLUS
 CN 15,17-Etheno-9H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-9-one, 6,7,8,10,11,12,13,21-octahydro-23-methoxy-7,8,8-trimethyl-, (CA INDEX NAME)




RN 1001433-12-0 ZCAPLUS
 CN 1-Piperidineethanol, α-[(6,7,8,9,10,11,12,20-octahydro-7-methyl-14,16-etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-


L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 1001433-15-3 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-22-[2-(2-methoxyethoxy)ethoxy]-7-methyl-, (CA INDEX NAME)




RN 1001433-16-4 ZCAPLUS
 CN Ethanol, 2-[methyl[3-[(6,8,9,10,11,12,13,21-octahydro-7-methyl-15,17-etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-23-yl)oxy]propyl]amino]- (CA INDEX NAME)




RN 1001433-17-5 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxatriazacyclonhexadecine, 4-bromo-6,7,8,9,10,11,12,20-octahydro-22-methoxy-, (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)
 b)[6,1,12]benzoxatriazacyclonhexadecin-22-yl)oxy]methyl]-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1001433-13-1 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxatriazacyclonhexadecine, 6,7,8,9,10,11,12,20-octahydro-22-(2-methoxyethoxy)-7-methyl-, (CA INDEX NAME)




RN 1001433-14-2 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)

L15 ANSWER 6 OF 7 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 1001433-18-6 ZCAPLUS
 CN 14,16-Etheno-1,3-dioxolo[4,5-g]pyrimido[4,5-b][6,1,12]benzoxatriazacyclonhexadecine, 6,7,8,9,10,11,12,20-octahydro-7-methyl-22-[3-(4-methyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 1001433-19-7 ZCAPLUS
 CN 15,17-Etheno-7H-[1,3]dioxolo[4,5-r]pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecine, 6,8,9,10,11,12,13,21-octahydro-7-methyl-23-[3-(4-(methylsulfonyl)-1-piperidinyl)propoxy]- (CA INDEX NAME)

L15 ANSWER 6 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


PAGE 1-A



PAGE 2-A

L15 ANSWER 7 OF 7 SCAPLUS COPYRIGHT 2009 ACS on SIN

AN 2006:1330060 SCAPLUS
DN 146:229297
TI Synthesis of new flat polynheterocyclic systems, potential DNA
intercalating agents. Diazines Part 47
AU Audoux, Jerome; Achelle, Sylvain; Turck, Alain; Marsais, Francis; Pie,
Nelly
CS Institut de Recherche en Chimie Organique Fine (I.R.C.O.F.), Universite de
Rouen, Mont Saint-Aignan, F-76133, Fr.
SO Journal of Heterocyclic Chemistry (2006), 43(6), 1497-1503
CODEN: JHICAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 146:229297
AB Using a regioselective metalation in connection with Stille cross-coupling
reaction, various flat tetra- or pentaheterocyclic compds. were obtained
which could be potential intercalating DNA agents.
IT 924309-43-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of new flat polynheterocyclic systems as potential DNA
intercalating agents)
RN 924309-43-3 SCAPLUS
CN 7H-Benzo[c]pyrimido[4,5,6-ij][2,6]naphthyridine, 5-(1,1-dimethylethyl)-
(CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 114 tot

L14 ANSWER 1 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 2006:578288 SCAPLUS
 DN 145:62924
 TI Preparation of quinazoline derivatives as multi targeting kinase
 inhibitors
 IN Freyne, Eddy Jean Edgard; Willems, Marc; Ten Holte, Peter; Papanikos,
 Alexandra; Embrechts, Werner Constant Johan; Storck, Pierre Henri;
 Poncellet, Virginie Sophie
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006061417	A2	20060615	2005WO-EP0056609	20051208 <--
WO--2006061417	A3	20060803		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, ME, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
FW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TK			
AU--2005313350	A1	20060615	2005AU-000313350	20051208 <--
CA--2588764	A1	20060615	2005CA-002588764	20051208 <--
EP--1328201	A2	20070905	2005EP-000826362	20051208 <--
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN--101072781	A	20071114	2005CN-080042043	20051208 <--
JP--2008523034	T	20080703	2007JP-000544918	20051208 <--
BR--200518394	A2	20081118	2005BR-000018394	20051208 <--
IN--200704039	A	20070831	2007IN-000004039	20070529 <--
MX--2007006820	A	20070724	2007MX-000006820	20070607 <--
ZA--2007005046	A	20080925	2007ZA-000005046	20070607 <--
KR--2007086030	A	20070827	2007KR-000713133	20070611 <--
NO--2007003436	A	20070705	2007NO-000003426	20070705 <--
PRAI 2004EP-000106383	A	20041208		
2004US-00634228P	P	20041208		
2004EP-000106385	A	20041208		
2005WO-EP0056609	W	20051208		
OS CASREACT 145:62924; MARPAT 145:62924				
GI				




AB Title compds. represented by the formula I (wherein Z = NH; Y = alkyl(oxy)alkyl, alkenyl, alkyl-NHCO, etc.; X1 = O, -O(alkyl), -O-NH-CH=, (un)substituted amino(alkyl); X2 = a direct bond, alkyl, amino, etc.; R1 = H, cyano, halo or hydroxy; R2 = H, cyano, halo, etc.; R3 = H, cyano,

formyl, etc.; R4 = (un)substituted (phenyl)alkyl(oxy); and n-oxides, pharmaceutically acceptable addn. salts and the stereochem. isomeric forms thereof) were prepd. as multi targeting kinase inhibitors (MTKI). For example, II was provided in a multi-step synthesis starting from N-[(4-chloro-2-nitrophenyl)acetyl]glycine Et ester. I were tested for inhibition of Abl human, CDK5/p35 human, cSRC human and the other kinases. Thus, I and their pharmaceutical compns. are useful as MTKI for the treatment of cell proliferation disorders, such as atherosclerosis, restenosis and cancer (no data).


II 807641-08-3P 890532-88-4P 890532-90-8P
 890532-92-0P 890532-94-2P 890532-96-4P
 890532-98-6P 890533-00-3P 890533-01-4P
 890533-02-5P 890533-03-6P 890533-04-7P
 890533-05-8P 890533-06-9P 890533-07-0P
 890533-08-1P 890533-09-2P 890533-10-5P
 890533-11-6P 890533-12-7P 890533-13-8P
 890533-14-9P 890533-15-0P

RN [Preparation of quinazoline derivs. as multi targeting kinase inhibitors]
 RN 807641-08-3 SCAPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-10-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 890532-88-4 SCAPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 21-[3-[(2-(acetyloxy)ethyl)methylamino]propoxy]-18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-13,14-dimethyl-, (13S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 890532-90-8 SCAPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-[3-[(2-hydroxyethyl)methylamino]propoxy]-13,14-dimethyl-, (13S)- (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 1 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 890532-92-0 SCAPLUS
 CN Acetamide, N-[2-[[3-[[[(13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-21-yl]oxy]propyl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 890532-94-2 SCAPLUS
 CN Acetamide, N-[2-[[3-[[[(13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-21-yl]oxy]propyl]amino]ethyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 890532-96-4 SCAPLUS
 CN Acetamide, N-[2-[[4-[[3-[[[(13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-21-yl]oxy]propyl]-1-piperazinyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 1 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 890532-98-6 SCAPLUS
 CN 4,6-Etheneopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-ethynyl-1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)-11-[3-(4-morpholinyl)propyl]-, (13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890533-00-3 SCAPLUS
 CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-13-(cyclohexylmethyl)-8,9,10,11,13,14,17,22-octahydro-23-methoxy-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890533-01-4 SCAPLUS


L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclohexadecine,
 17-ethynyl-1,8,9,10,11,12,13,14-octahydro-20-[(2-methoxyethoxy)ethoxy]-
 13-methyl- (CA INDEX NAME)



RN 890533-02-5 ZCAPLUS
 CN 8H-4,6-Ethno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,
 18-bromo-17-fluoro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-
 11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 890533-03-6 ZCAPLUS
 CN Carbamic acid, [3-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-yl)oxy]propyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 890533-04-7 ZCAPLUS
 CN 4-Thiomorpholineethanol, α-[(17-bromo-1,8,9,10,11,12,13,14-
 octahydro-13-methyl-4,6-ethenopyrimido[4,5-
 b][6,1,12]benzoxadiazacycloptadec-20-yl)oxy]methyl]-, 1,1-dioxide,
 (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-05-8 ZCAPLUS
 CN Acetamide, N-[2-[(3-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-
 4,6-ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-
 yl)oxy]propyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 890533-06-9 ZCAPLUS
 CN 1-Propanamine, 3-[(17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-yl)oxy]-N-[2-
 (methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 890533-07-0 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-
 dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy-11-[2-(4-
 morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 890533-08-1 ZCAPLUS
 CN 8H-4,6-Ethno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine,
 18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-
 11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 890533-09-2 ZCAPLUS
 CN 2-Propanol, 3-[(17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-13-
 methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-
 yl)oxy]-3-[(2-(2-hydroxyethoxy)ethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890533-10-5 ZCAPLUS
 CN 1-Propanamine, 3-[(17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-13-
 methyl-4,6-ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-
 yl)oxy]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 890533-11-6 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadecine,
 17-chloro-20-[3-(1,3-dioxido-4-thiomorpholinyl)propoxy]-16-fluoro-
 1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)




RN 890533-12-7 ZCAPLUS
 CN 1-Propanamine, 3-[(17-ethynyl-1,8,9,10,11,12,13,14-octahydro-13-methyl-4,6-
 ethenopyrimido[4,5-b][6,1,12]benzoxadiazacycloptadec-20-yl)oxy]-N-[2-
 (methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)




RN 890533-13-8 ZCAPLUS
 CN Spiro[16H-4,6-etheno-6H-pyrimido[4,5-
 b][6,1,10,13]benzoxatriazacyclooctadecine-13(14H),1'-cyclohexane]-12,15-
 dione, 20-chloro-8,9,10,11,17,22-hexahydro-23-methoxy- (CA INDEX NAME)


L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)



RN 890533-14-9 ZCAPLUS
CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-ol, 18-bromo-17-fluoro-9,10,11,12,13,14,15,20-octahydro-14-methyl-11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




RN 890533-15-0 ZCAPLUS
CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-ol, 18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-14-methyl-11-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)




IT 890532-56-6P 890532-65-7P 890532-76-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as multi targeting Kinase inhibitors for

L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




IT 807640-87-5P 890532-53-3P 890532-54-4P
890532-55-5P 890532-57-7P 890532-66-8P
890532-75-9P 890532-77-1P 890532-84-0P
890532-85-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as multi targeting Kinase inhibitors for treatment of cell proliferation disorders)
RN 807640-87-5 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)



RN 890532-53-3 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-54-4 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-hydroxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)


treatment of cell proliferation disorders)
RN 890532-56-6 ZCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-[[[(13S)-18-chloro-17-fluoro-9,10,11,12,13,14,15,20-octahydro-13,14-dimethyl-12-oxo-8H-4,6-etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-21-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-65-7 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-bromo-1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-[2-methylpropyl]-11-[3-(4-morpholinyl)propyl]-, (13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 890532-76-0 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-[2-(2-methoxyethoxy)ethoxy]-13-methyl- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2009 ACS ON STN (Continued)




RN 890532-55-5 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 890532-57-7 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-, (13S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 890532-66-8 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)-11-[3-(4-morpholinyl)propyl]-19-[(trimethylsilyl)ethynyl]-, (13S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 1 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 890532-75-9 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin-20-ol, 17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)




RN 890532-77-1 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin, 1,8,9,10,11,12,13,14-octahydro-20-(2-(2-methoxyethoxy)ethoxy)-13-methyl-17-(2-(trimethylsilyl)ethynyl)- (9CI) (CA INDEX NAME)




RN 890532-84-0 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin, 17-bromo-1,8,9,10,11,12,13,14-octahydro-13-methyl-20-((2S)-oxiranylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 890532-85-1 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecin, 17-bromo-20-(3-bromopropoxy)-1,8,9,10,11,12,13,14-octahydro-13-methyl- (9CI) (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN

AN 2004:1059178 ZCAPLUS
 DN 142:38270
 TI A preparation of macrocyclic quinazoline derivatives, useful as antiproliferative agents
 TN Freyne, Eddy Jean Edgard; Perera, Timothy Pietro Suren; Buijnstens, Peter Jacobus Johannes Antonius; Willems, Marc; Diele, Gaston Stanislas Marcella; Embrechts, Werner Constant Johan; Ten Holte, Peter Janssen Pharmaceutica N.V., Belg.
 PA PCT Int. Appl., 196 pp.
 SO CODEN: PIXXD2

DT Patent
 LA English

FAR.CYT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-----2004105765	A1	20041209	2004WO-EP0005621	20040525 <--
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, US, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NE, NA, SD, SL, SE, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU---2004243487	A1	20041209	2004AU-000243487	20040525 <--
CA-----2525214	A1	20041209	2004CA-002525214	20040525 <--
EP-----1423265	A1	20060215	2004EP-000739341	20040525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR---2004010714	A	20060613	2004BR-00010714	20040525 <--
CN-----1794996	A	20060628	2004CN-080014512	20040525 <--
JP---2007504276	T	20070301	2006JP-000529915	20040525 <--
NZ-----544154	A	20090131	2004NZ-000544154	20040525 <--
IN---200505320	A	20080104	2005IN-000005320	20051121 <--
US-20060247237	A1	20061102	2005US-00058007	20051122 <--
ZA---2005009541	A	20070228	2005ZA-000009541	20051124 <--
MX---2005012762	A	20060213	2005MX-000012762	20051125 <--
NO---2005006196	A	20051228	2005NO-000006196	20051227 <--
PRAI 2003WO-EP0005723	A	20030527	<--	
2003WO-EP0010266	A	20030915	<--	
2003WO-EP0051061	A	20031218	<--	
2004WO-EP0005621	W	20040525	<--	
OS MARPAT 142:38270				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a preparation of macrocyclic derivs. of formula I [wherein: Z is O, CH₂, NH, or S; Y is alk(en)ynyl, alkyl-C(O)NH, C(O)alkyl, or C(O)NH-alkyl, etc.; X1 and X2 are independently selected from a direct bond, O, 0-alkyl, CH₂, or ON-CH₂, etc.; R1 is H, CN, halogen, OH, CHO, or alkyl, etc.; R2 is H, CN, OH, alkylcarbonyl, or aminocarbonyl, etc.; R3 is H or alkyl; R4 is H, OH, aryloxy, alkoxy, or alkenyloxy, etc.], useful as antiproliferative agents. For instance, pyrimidobenzo[diazacyclopentadecine derivative II (kinase activity: pIC₅₀ = 7.8, A431 cell (C5); pIC₅₀ < 6) was prepared via intramolecular heterocyclization/etherification of the prepared quinazoline derivative III.

IT 807639-89-0P 807640-75-1P 807640-80-8P 807640-81-9P 807640-84-2P 807640-94-4P 807640-96-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents).

RN 807639-89-0 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 807640-75-1 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine-17-carboxylic acid, 8,9,10,11,12,13-hexahydro-20-methoxy-, methyl ester (CA INDEX NAME)



RN 807640-80-8 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-(phenylmethoxy)- (CA INDEX NAME)




RN 807640-81-9 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 807640-84-2 ZCAPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-13(8H)-carboxylic acid, 17-bromo-9,10,11,12,14,19-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 807640-94-4 ZCAPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-13(8H)-carboxylic acid, 17-chloro-16-fluoro-9,10,11,12,14,19-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 807640-96-6 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine-12(1H)-carboxylic acid, 17-chloro-8,9,10,11,13,14-hexahydro-20-methoxy-, 1,1-dimethylethyl ester (FCT) (CA INDEX NAME)




II 807640-67-1P 807640-68-2P 807640-69-3P
 807640-70-6P 807640-71-7P 807640-72-8P
 807640-73-9P 807640-74-0P 807640-76-2P
 807640-77-3P 807640-78-4P 807640-79-5P
 807640-82-0P 807640-83-1P 807640-85-3P
 807640-86-4P 807640-87-5P 807640-88-6P
 807640-89-7P 807640-90-0P 807640-91-1P
 807640-93-3P 807640-94-4P 807640-97-7P

L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)


15-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807640-69-3 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807640-70-6 ZCAPLUS
 CN 18H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,12,1]benzodioxazacyclotetradecine, 16-chloro-9,10,11,12-tetrahydro-19-methoxy- (CA INDEX NAME)




RN 807640-71-7 ZCAPLUS
 CN 18H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,12,1]benzodioxazacyclotetradecine, 9,10,11,12-tetrahydro-19-methoxy- (CA INDEX NAME)

L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)

807640-98-9P 807641-00-5P 807641-01-6P 807641-02-7P 807641-03-8P
 807641-04-9P 807641-05-0P 807641-06-1P
 807641-07-2P 807641-08-3P 807641-09-4P
 807641-10-7P 807641-11-8P 807641-12-9P
 807641-13-0P 807641-14-1P 807641-15-2P
 807641-16-3P 807641-17-4P 807641-18-5P
 807641-19-6P 807641-20-6P 807641-21-0P
 807641-22-1P 807641-23-2P 807641-24-3P
 807641-25-4P 807641-26-5P 807641-27-6P
 807641-28-7P 807641-29-8P 807641-30-1P
 807641-31-2P 807641-32-3P 807641-33-4P
 807641-34-5P 807641-35-6P 807641-36-7P
 807641-37-8P 807641-38-9P 807641-39-0P
 807641-40-3P 807641-41-4P 807641-42-5P
 807641-43-6P 807641-44-7P 807641-45-8P
 807641-46-9P 807641-47-0P 807641-48-1P
 807641-49-2P 807641-50-3P 807641-51-6P
 807641-52-7P 807641-53-8P 807641-54-9P
 807641-55-0P 807641-56-1P 807641-57-2P
 807641-58-3P 807641-59-4P 807641-60-7P
 807641-61-8P 807641-62-9P 807641-63-0P
 807641-64-1P 807641-65-2P 807641-66-3P
 807641-67-4P 807641-68-5P 807641-69-6P
 807641-70-9P 807641-71-0P 807641-72-1P
 807641-73-2P 807641-74-3P 807641-75-4P
 807641-76-5P 807641-77-6P 807641-78-7P
 807641-79-8P 807641-80-1P 807641-81-2P
 807641-82-3P 807641-83-4P 807641-84-5P
 807641-85-6P 807641-86-7P 807641-87-8P
 807641-88-9P 807641-89-0P 807641-90-3P
 807641-91-4P 807641-92-5P 807641-93-6P
 807641-94-7P 807641-95-8P 807641-97-0P
 807641-98-1P 807641-99-2P 807642-00-8P
 807642-01-9P 807642-02-0P 807642-03-1P
 807642-04-2P 807642-05-3P 807642-06-4P
 807642-07-5P 807642-08-6P 807642-09-7P
 807642-10-0P 807642-11-1P 807642-12-2P
 807642-13-3P 807642-14-4P 807642-15-5P
 807642-17-7P 807642-18-8P 807642-19-9P
 807642-20-2P 807642-21-3P 807642-22-4P
 807642-23-5P 807642-24-6P 807642-25-7P
 807642-26-8P 807642-27-9P 807642-28-0P
 807642-29-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOU (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of macrocyclic quinoxaline derivs. useful as antiproliferative agents)

RN 807640-67-1 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 8(9H)-one, 10,11,12,13-tetrahydro-20-methoxy-15-methyl- (CA INDEX NAME)




RN 807640-68-2 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine,


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807640-72-8 ZCAPLUS
 CN 20H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,14,1]benzodioxazacyclonhexadecine, 18-chloro-9,10,11,12,13,14-hexahydro-21-methoxy- (CA INDEX NAME)



RN 807640-73-9 ZCAPLUS
 CN 21H-4,6-Etheno-6H-pyrimido[4,5-b][6,15,1]benzodioxazacycloheptadecine, 19-chloro-8,9,10,11,12,13,14,15-octahydro-22-methoxy- (CA INDEX NAME)




RN 807640-74-0 ZCAPLUS
 CN 22H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,16,1]benzodioxazacyclooctadecine, 20-chloro-9,10,11,12,13,14,15,16-octahydro-23-methoxy- (CA INDEX NAME)




RN 807640-76-2 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine-17-


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 carboxylic acid, 8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807640-77-3 ZCAPLUS
 CN Methanone, (8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-17-yl)-1-pyrrolidinyl- (CA INDEX NAME)




RN 807640-78-4 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-17-carbonitrile, 8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807640-79-5 ZCAPLUS
 CN Methanone, (8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-17-yl)-4-morpholinyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807640-86-4 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1]benzoxazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)



RN 807640-87-5 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN 807640-88-6 ZCAPLUS
 CN 13H-4,6-Etheno-6H-pyrimido[4,5-b][6,11,1]benzodioxazacyclopentadecine, 17-chloro-8,9,10,11,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807640-89-7 ZCAPLUS


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807640-82-0 ZCAPLUS
 CN 19H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,12,1]benzodioxazacyclopentadecine, 16-bromo-9,10,11,12-tetrahydro-19-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)




RN 807640-83-1 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro- (CA INDEX NAME)




RN 807640-85-3 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 CN 23H-4,6-Etheno-6H-pyrimido[4,5-b][6,15,1,16]benzodioxadiazacyclononadecine, 21-chloro-8,9,10,11,12,13,14,15-octahydro-24-methoxy- (CA INDEX NAME)



RN 807640-90-0 ZCAPLUS
 CN 18H-4,6-Etheno-17,21-methenopyrimido[5,4-d][1,12,6]dioxazacycloicosine, 8,9,10,11,12,13,14,15-octahydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807640-91-1 ZCAPLUS
 CN 4,6-Ethenopyrimido[4,5-b][6,1,10]benzoxadiazacyclopentadecin-12(1H)-one, 17-chloro-8,9,10,11,13,14-hexahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-93-3 ZCAPLUS
 CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecine, 17-bromo-8,9,10,11,12,13-hexahydro-20-(2-methoxyethoxy)- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807640-95-5 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-chloro-16-fluoro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-97-7 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,11]benzoxadiazacyclopentadecine, 17-chloro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807640-98-8 ZCAPLUS
CN 19H-4,6-Etheno-6H-pyrimido[5,4-k][1,8,5,13]benzodioxadiacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-20-methoxy-10-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 807641-02-7 ZCAPLUS
CN 14H-4,6-Etheno-6H,8H-pyrimido[4,5-b][6,1,2,1]benzodioxatriacyclohexadecin-12(13H)-one, 18-chloro-9,10,11,12,15,20-hexahydro-21-methoxy- (CA INDEX NAME)



RN 807641-03-8 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,11]benzoxadiazacyclohexadecin-11(8H)-one, 18-chloro-9,10,12,13,14,15-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-04-9 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriacycloheptadecin-12(13H)-one, 19-chloro-8,9,10,11,14,15,16,21-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-05-0 ZCAPLUS


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807640-99-9 ZCAPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxadiacyclopentadecine, 8,9,10,11,12,13-hexahydro-20-methoxy-17-phenyl- (CA INDEX NAME)




RN 807641-00-5 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,13]benzoxadiazacyclohexadecin-15(8H)-one, 18-chloro-9,10,11,12,13,14-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-01-6 ZCAPLUS
CN 19H-4,6-Etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxadiacyclopentadecine, 16-chloro-8,9,10,11,12,13-hexahydro-20-methoxy- (CA INDEX NAME)

L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriacycloheptadecin-12(13H)-one, 19-chloro-8,9,10,11,14,15,16,21-octahydro-10-[(2-hydroxyethyl)amino]acetyl-22-methoxy- (9CI) (CA INDEX NAME)



RN 807641-06-1 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriacycloheptadecin-12(13H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-methyl- (9CI) (CA INDEX NAME)




RN 807641-07-2 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-16-fluoro-1,8,9,10,11,12,13,14-octahydro-20-methoxy- (9CI) (CA INDEX NAME)




RN 807641-08-3 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriacyclohexadecin-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-10-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-09-4 ZCAPLUS
CN Benzamide, 4-fluoro-N-(8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-16-yl)- (CA INDEX NAME)




RN 807641-10-7 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12,12-dimethyl- (9CI) (CA INDEX NAME)



RN 807641-11-8 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,10,14]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

Double bond geometry as described by E or Z.



RN 807641-15-2 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,16]benzoxadiazacyclononadecin-16(1H)-one, 21-chloro-8,9,10,13,14,15,17,18-octahydro-24-methoxy- (11Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 807641-16-3 ZCAPLUS
CN Carbamic acid, [(11E,14S)-20-chloro-8,9,10,13,14,15,16,17-octahydro-23-methoxy-15-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-14-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 807641-12-9 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[2,1-m][6,1,11,14]benzoxatriazacyclononadecin-13(8H)-one, 21-chloro-1,9,10,11,12,13a,14,15,16,18-decahydro-24-methoxy-, (13aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-13-0 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[2,1-m][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 20-chloro-19-fluoro-1,8,9,10,11,12a,13,14,15,17-decahydro-23-methoxy-, (12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-14-1 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,16]benzoxadiazacyclononadecin-16(1H)-one, 21-chloro-8,9,10,13,14,15,17,18-octahydro-24-methoxy-, (11E)- (9CI) (CA INDEX NAME)

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-17-4 ZCAPLUS
CN Carbamic acid, [(11Z,14S)-20-chloro-8,9,10,13,14,15,16,17-octahydro-23-methoxy-15-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-14-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as described by E or Z.

RN 807641-18-5 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,15]benzoxadiazacyclooctadecin-15(8H)-one, 14-amino-20-chloro-9,10,13,14,16,17-hexahydro-23-methoxy-, dihydrochloride, (14S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)

PAGE 1-A




● 2 HCl

RN 807641-19-6 SCAPLUS
CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-18-chloro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA INDEX NAME)




RN 807641-20-9 SCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine-17-chloro-1,8,9,12,13,14-hexahydro-20-methoxy-13-methyl-, (102)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 807641-25-4 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-methyl-, (CA INDEX NAME)



RN 807641-26-5 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-(1-methylethyl)- (CA INDEX NAME)




RN 807641-27-6 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-(phenylmethyl)- (CA INDEX NAME)

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)


RN 807641-21-0 SCAPLUS

CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclonexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11-methyl-, (115)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 807641-22-1 SCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,9,14]benzoxatriazacycloheptadecine-9,14(8H,15H)-dione, 19-chloro-10,11,12,13,16,21-hexahydro-22-methoxy- (CA INDEX NAME)




RN 807641-23-2 SCAPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 19-chloro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-24-3 SCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-25-4 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-methyl-, (CA INDEX NAME)




RN 807641-26-5 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11-(1-methylethyl)- (CA INDEX NAME)




RN 807641-27-6 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-(phenylmethyl)- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-28-7 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-29-8 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-methyl-, (CA INDEX NAME)




RN 807641-30-1 SCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy-11-(1-methylethyl)- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-31-2 ZCAPLUS
CN 19H-9,11-Ethenopyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclopentadecine-14,19(5H,13H)-dione, 16,17,18,18a,20,21-hexahydro-22-methoxy- (CA INDEX NAME)




RN 807641-32-3 ZCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 10,11,14,19-tetrahydro-20-methoxy- (CA INDEX NAME)




RN 807641-33-4 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclohexadecine-9,13(8H,10H)-dione, 11,12,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-38-9 ZCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,12,16]benzoxatriazacyclononadecine-12,16-dione, 21-chloro-8,9,10,11,13,14,15,17,18,23-decahydro-24-methoxy- (CA INDEX NAME)




RN 807641-39-0 ZCAPLUS
CN 18H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,17]benzoxatriazacycloicosine-12,17-dione, 22-chloro-8,9,10,11,13,14,15,16,19,24-decahydro-25-methoxy- (CA INDEX NAME)




RN 807641-40-3 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-10-methyl- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-34-5 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,9,14]benzoxatriazacycloheptadecine-9,14(8H,15H)-dione, 10,11,12,13,16,21-hexahydro-22-methoxy- (CA INDEX NAME)



RN 807641-35-6 ZCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-10-methyl- (CA INDEX NAME)




RN 807641-36-7 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-37-8 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,14]benzoxatriazacyclooctadecine-9,14(8H,15H)-dione, 20-chloro-10,11,12,13,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-41-4 ZCAPLUS
CN Carbamic acid, (18-chloro-8,9,10,11,12,13,14,15-octahydro-21-methoxy-13-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,12]benzoxadiacyclohexadecin-12-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 807641-42-5 ZCAPLUS
CN 19H-9,11-Ethenopyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclopentadecine-14,19(5H,13H)-dione, 3-chloro-16,17,18,18a,20,21-hexahydro-22-methoxy- (CA INDEX NAME)




RN 807641-43-6 ZCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-11-(1-hydroxyethyl)-20-methoxy- (CA INDEX NAME)




RN 807641-44-7 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-9,14(8H,15H)-dione, 10,11,12,13,16,21-hexahydro-22-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 13, 14(8H, 15H)-dione, 19-chloro-9, 10, 12, 13, 16, 21-hexahydro-22-methoxy-13-(1-methylethyl)- (CA INDEX NAME)



RN 807641-45-8 ZCAPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-11-(hydroxymethyl)-20-methoxy- (CA INDEX NAME)




RN 807641-46-9 ZCAPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-13-(hydroxymethyl)-22-methoxy- (CA INDEX NAME)




RN 807641-47-0 ZCAPLUS
 CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-methyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-51-6 ZCAPLUS
 CN 8H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11,11-dimethyl- (CA INDEX NAME)




RN 807641-52-7 ZCAPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,13H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-10-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 807641-53-8 ZCAPLUS
 CN 22H-9,11-Etheno-13H-pyrimido[4,5-b]pyrrolo[1,2-i][6,1,12,15]benzoxatriazacyclooctadecine-17,22(5H,14H)-dione, 3-chloro-15,16,19,20,21,21a,23,24-octahydro-25-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-48-1 ZCAPLUS
 CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy-11,11-dimethyl- (CA INDEX NAME)




RN 807641-49-2 ZCAPLUS
 CN 19H-9,11-Ethenopyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclopentadecine-14,19(5H,13H)-dione, 3-chloro-16,17,18,18a,20,21-hexahydro-17-hydroxy-22-methoxy- (CA INDEX NAME)




RN 807641-50-5 ZCAPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,15]benzoxatriazacyclooctadecine-15(8H)-one, 20-chloro-9,12,13,14,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-54-9 ZCAPLUS
 CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11,11-dimethyl- (9CI) (CA INDEX NAME)




RN 807641-55-0 ZCAPLUS
 CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-13-methyl- (CA INDEX NAME)




RN 807641-56-1 ZCAPLUS
 CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-(2-methylpropyl)- (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-57-2 ZCAPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14,14-dimethyl- (CA INDEX NAME)




RN 807641-58-3 ZCAPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-(phenylmethyl)- (CA INDEX NAME)




RN 807641-59-4 ZCAPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-23-methoxy-14-methyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-63-0 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-11-(1-hydroxyethyl)-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-64-1 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13,13-dimethyl- (CA INDEX NAME)




RN 807641-65-2 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-(phenylmethyl)- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-60-7 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclohexadecine-9,14(8H,15H)-dione, 20-chloro-11,12,13,13a,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-61-8 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-22-methoxy-13-(2-methylpropyl)- (CA INDEX NAME)




RN 807641-62-9 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-21-methoxy-11-(2-methylpropyl)- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-66-3 ZCAPLUS
CN 16H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacyclooctadecine-12,15-dione, 20-chloro-8,9,10,11,13,14,17,22-octahydro-14-(1-hydroxyethyl)-23-methoxy- (CA INDEX NAME)




RN 807641-67-4 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-9,12(8H,13H)-dione, 18-chloro-10,11,14,15-tetrahydro-11-(hydroxymethyl)-21-methoxy- (9CI) (CA INDEX NAME)




RN 807641-68-5 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b]pyrrolo[1,2-i][6,1,9,12]benzoxatriazacyclohexadecine-9,14(8H,15H)-dione, 20-chloro-11,12,13,13a,16,17-hexahydro-12-hydroxy-23-methoxy- (9CI) (CA INDEX NAME)

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-69-6 ZCAPLUS
CN Carbamic acid, [(1145)-20-chloro-8,9,10,11,12,13,14,15,16,17-decahydro-23-methoxy-15-oxo-4,6-etheno-1H-pyrimido[4,5-b][6,1,15]benzoxatriazacyclooctadecine-14-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 807641-70-9 ZCAPLUS
CN 14H-4,6-Etheno-6H-pyrimido[4,5-b][6,9,12,1]benzotrioxaazacyclohexadecine, 18-chloro-8,9,11,12,15,20-hexahydro-21-methoxy- (CA INDEX NAME)




RN 807641-71-0 ZCAPLUS
CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy-13-methyl- (CA INDEX NAME)

L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 807641-75-4 ZCAPLUS
CN 12H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-9,12(8H,13H)-dione, 17-chloro-10,11,14,19-tetrahydro-20-methoxy- (CA INDEX NAME)



RN 807641-76-5 ZCAPLUS
CN 4,6-Etheno-8H-pyrimido[4,5-b]pyrrolo[2,1-l][6,1,10,13]benzoxatriazacyclohexadecine-12,15(9H,12aH)-dione, 20-chloro-1,10,11,13,14,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-77-6 ZCAPLUS
CN 4,6-Etheno-12H-pyrimido[4,5-b]pyrrolo[2,1-l][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 20-chloro-1,8,9,10,11,12a,13,14,15,17-decahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-78-7 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclohexadecine-9,13(8H,10H)-dione, 18-chloro-11,12,14,15-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 807641-72-1 ZCAPLUS
CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807641-73-2 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA INDEX NAME)




RN 807641-74-3 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,13]benzoxatriazacyclohexadecine-11(8H)-one, 18-chloro-9,10,12,13,14,15-hexahydro-21-methoxy- (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807641-79-8 ZCAPLUS
CN 16H-4,6-Ethenopyrimido[4,5-b][6,1,11,16]benzoxatriazacyclononadecine-11,16(8H,17H)-dione, 21-chloro-9,10,12,13,14,15,18,23-octahydro-24-methoxy- (CA INDEX NAME)




RN 807641-80-1 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,11,15]benzoxatriazacyclooctadecine-11,15(8H,12H)-dione, 20-chloro-9,10,13,14,16,17-hexahydro-23-methoxy- (9CI) (CA INDEX NAME)




RN 807641-81-2 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclohexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12-(1-methylethyl)- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-82-3 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclonhexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy-12-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 807641-83-4 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-chloro-1,8,9,10,11,13,14,16-octahydro-22-methoxy-13-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 807641-84-5 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,9,12]benzoxatriazacyclonhexadecine-11,14(8H,15H)-dione, 18-chloro-9,10,12,13-tetrahydro-21-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 807641-88-9 ZCAPLUS
CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-16-fluoro-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)



RN 807641-89-0 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807641-90-3 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807641-91-4 ZCAPLUS
CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-9,10,11,12,14,15,16,21-octahydro-22-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-85-6 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 19-chloro-18-fluoro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-86-7 ZCAPLUS
CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-16-fluoro-9,10,12,13,14,19-hexahydro-20-methoxy-13-methyl- (CA INDEX NAME)




RN 807641-87-8 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclonhexadecin-12-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-14-methyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-92-5 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-10-ethyl-8,9,10,11,13,14,15,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807641-93-6 ZCAPLUS
CN 1,12-Etheno-2H,17H-pyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacycloheptadecin-14(15H)-one, 7-chloro-10,11,12,13,18,19,19a,20-octahydro-24-methoxy- (9CI) (CA INDEX NAME)




RN 807641-94-7 ZCAPLUS
CN 4,6-Etheno-1H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclooctadecin-13(8H)-one, 20-chloro-9,10,11,12,14,15,16,17-octahydro-23-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-95-8 ZCAPLUS
CN 8H-4,6-Etheno-9,13-methano-1H-pyrimido[4,5-b][6,1,12,15]benzoxatriazacycloelcosin-15(14H)-one, 22-chloro-9,10,11,12,16,17,18,19-octahydro-26-methoxy- (9CI) (CA INDEX NAME)




RN 807641-97-0 ZCAPLUS
CN 1H-9,12-Ethano-4,6-ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacyclononadecin-14(13H)-one, 22-chloro-8,9,10,11,15,16,17,18-octahydro-26-methoxy- (9CI) (CA INDEX NAME)




RN 807641-98-1 ZCAPLUS
CN 8H-10,13-Ethano-4,6-ethenopyrimido[4,5-b][6,1,12,15]benzoxatriazacycloelcosin-15(14H)-one, 22-chloro-9,10,11,12,16,17,18,19-octahydro-27-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807642-02-0 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-10-[[12-(dimethylamino)ethyl]methylamino]acetyl-8,9,10,11,13,14,15,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-03-1 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(2-methoxyethyl)amino]acetyl- (9CI) (CA INDEX NAME)




RN 807642-04-2 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(3-methoxypropyl)amino]acetyl- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807641-99-2 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-10-[[2-(hydroxymethyl)ethyl]amino]acetyl-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-00-8 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-4-morpholinylacetyl-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-01-9 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(4-pyridinyl)ethyl]amino]acetyl- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807642-05-3 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-(4-morpholinylacetyl)- (9CI) (CA INDEX NAME)




RN 807642-06-4 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacycloheptadecin-12(1H)-one, 19-chloro-8,9,10,11,13,14,15,16-octahydro-22-methoxy-10-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 807642-07-5 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-n][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 23-chloro-20-fluoro-1,9,10,11,12,13a,14,15,16,18-decahydro-24-methoxy- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807642-08-6 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecine-11(8H)-thione, 19-chloro-18-fluoro-1,9,10,11a,12,13,14,16-octahydro-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-09-7 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine, 19-chloro-1,8,9,10,11,12,13,14,15,16-decahydro-22-methoxy-15-methyl- (9CI) (CA INDEX NAME)




RN 807642-10-0 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine, 17-chloro-1,8,9,10,11,12,13,14-octahydro-20-methoxy-13-methyl- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807642-14-4 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-13(8H)-one, 19-chloro-15-ethyl-9,10,11,12,14,15,16,21-octahydro-22-methoxy- (CA INDEX NAME)




RN 807642-15-5 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-13(8H)-one, 19-chloro-9,10,11,12,14,15,16,21-octahydro-22-methoxy-14,15-dimethyl- (CA INDEX NAME)




RN 807642-17-7 ZCAPLUS
CN Benzotriazole, 3-(8,9,10,11,12,13-hexahydro-20-methoxy-19H-4,6-etheno-6H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-17-yl)- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



RN 807642-11-1 ZCAPLUS
CN 14H-4,6-Ethenopyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine-11,14(8H,15H)-dione, 19-chloro-9,10,12,13,16,21-hexahydro-13-(1-hydroxyethyl)-22-methoxy- (CA INDEX NAME)




RN 807642-12-2 ZCAPLUS
CN 12H-4,6-Etheno-13,17-methanopyrimido[4,5-b][6,1,10,16]benzoxatriazacyclononadecin-12-one, 21-chloro-1,8,9,10,11,13,14,15,16-decahydro-25-methoxy- (CA INDEX NAME)




RN 807642-13-3 ZCAPLUS
CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl- (CA INDEX NAME)


L14 ANSWER 2 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)




RN 807642-18-8 ZCAPLUS
CN 4,6-Ethenopyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 19-chloro-1,9,10,11a,12,13,14,16-octahydro-13-hydroxy-22-methoxy- (9CI) (CA INDEX NAME)




RN 807642-19-9 ZCAPLUS
CN 13,16-Ethano-4,6-etheno-8H-pyrimido[4,5-b][6,1,9,12,15]benzoxatetraazacyclooctadecin-11(12H)-one, 20-chloro-1,9,10,14,15,17-hexahydro-25-methoxy- (9CI) (CA INDEX NAME)




RN 807642-20-2 ZCAPLUS
CN 8H-12,15-Ethano-4,6-ethenopyrimido[4,5-b][6,1,9,14]benzoxatriazacycloheptadecin-11(12H)-one, 19-chloro-1,9,10,13,14,16-hexahydro-24-methoxy- (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)
 RN 807642-21-3 ZCAPLUS
 CN 4,6-Etheno-12,16-methano-16H-pyrimido[4,5-b][6,1,9,15]benzoxatriazacyclooctadecin-11(8H)-one, 20-chloro-1,9,10,12,13,14,15,17-octahydro-24-methoxy- (9CI) (CA INDEX NAME)



RN 807642-22-4 ZCAPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-20-methoxy-12,13-dimethyl- (CA INDEX NAME)




RN 807642-23-5 ZCAPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-13-ethyl-9,10,12,13,14,19-hexahydro-20-methoxy- (CA INDEX NAME)




RN 807642-24-6 ZCAPLUS
 CN 8H-4,6-Ethenopyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 17-chloro-9,10,12,13,14,19-hexahydro-12-(hydroxymethyl)-20-methoxy- (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807642-28-0 ZCAPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-12-one, 18-chloro-14-ethyl-8,9,10,11,13,14,15,20-octahydro-21-methoxy- (CA INDEX NAME)




RN 807642-29-1 ZCAPLUS
 CN 12H-4,6-Etheno-6H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclononadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-13-(hydroxymethyl)-21-methoxy- (CA INDEX NAME)




IT **807639-88-99**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of macrocyclic quinazoline derivs. useful as antiproliferative agents)

RN 807639-88-9 ZCAPLUS
 CN Boronic acid, (8,9,10,11,12,13-hexahydro-20-methoxy-4,6-etheno-1H-pyrimido[4,5-b][6,13,1]benzodioxazacyclopentadecin-17-yl)- (9CI) (CA INDEX NAME)


L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 807642-25-7 ZCAPLUS
 CN 4,6-Etheno-12H-pyrimido[4,5-b]pyrrolo[2,1-b][6,1,10,13]benzoxatriazacyclononadecin-12-one, 20-chloro-1,8,9,10,11,12a,13,14,15,17-decahydro-14-hydroxy-23-methoxy- (9CI) (CA INDEX NAME)




RN 807642-26-8 ZCAPLUS
 CN 14,17-Ethano-4,6-ethenopyrimido[4,5-b][6,1,10,13,16]benzoxatetraazacyclononadecin-12(13H)-one, 21-chloro-1,8,9,10,11,15,16,18-octahydro-26-methoxy- (9CI) (CA INDEX NAME)




RN 807642-27-9 ZCAPLUS
 CN 13,16-Ethano-4,6-etheno-16H-pyrimido[4,5-b][6,1,10,15]benzoxatriazacyclooctadecin-12(13H)-one, 20-chloro-1,8,9,10,11,14,15,17-octahydro-25-methoxy- (9CI) (CA INDEX NAME)

L14 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN (Continued)




OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN
 AN 1994:65665 SCAPLUS
 DN 121:255685
 OREF 121:46679a
 TI [4 + 2]-Cycloadditions of 3-amino-4-imino-4H-thieno[3,4-c][1]benzopyran
 with some selected dienophiles
 AU Nyilondi-Bonguen, E.; Sopue Fondjo, E.; Tanee Fomum, Z.; Doepp, Dietrich
 CS Fac. Sci., Univ. Yaounde, Yaounde, Cameroon
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1994), (15), 2191-5
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 121:255685
 GI




AB 3-Amino-4-imino-4H-thieno[3,4-c][1]benzopyran (I) adds di-Me maleate and
 di-Me acetylenedicarboxylate in a [4 + 2] mode across the thiophene ring
 and reacts with 2,3-dichloro-1,4-naphthoquinone by substitution of both
 chlorine atoms. All primary adducts, however, are unstable under the
 reaction conditions. The structures of the final products, e.g. II, have
 been assigned from their spectral data and their formation has been
 rationalized in terms of transformations available to the assumed primary
 products.
 IT **158529-61-4P** **158529-62-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 158529-61-4 SCAPLUS
 CN [1]Benzopyrano[2,3,4-de]quinazoline-2,3-dicarboxylic acid, 5-methyl-,
 2,3-dimethyl ester (CA INDEX NAME)




RN 158529-62-5 SCAPLUS
 CN [1]Benzopyrano[2,3,4-de]quinazoline-2,3-dicarboxylic acid,
 5-(trifluoromethyl)-, 2,3-dimethyl ester (CA INDEX NAME)

L14 ANSWER 4 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN
 AN 1971:22728 SCAPLUS
 DN 74:22728
 OREF 74:3675a,3678a
 TI Reactions of 4-dicyanomethylene-2-phenyl-4H-1-benzopyran and some
 benzologs with nucleophiles
 AU Reynolds, George Arthur; VanAllan, James A.; Petropoulos, C. C.
 CS Res. Lab., Eastman Kodak Co., Rochester, NY, USA
 SO Journal of Heterocyclic Chemistry (1970), 7(5), 1061-9
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 74:22728
 GI For diagram(s), see printed CA Issue.
 AB 4-Dicyanomethylene-2-phenyl-4H-1-benzopyran (I) reacts with primary amines
 under mild conditions to give 4-imino-3-alkyl-5-alkylimino-2-phenyl-3,4-
 dihydro-5H-[1]benzopyrano[3,4-c]pyridine derivs. (II) which, in turn, are
 hydrolyzed with acid to 4-imino-3-alkyl-2-phenyl-3,4-dihydro-5H-
 [1]benzopyrano[3,4-c]pyridin-5-ones. When more vigorous conditions are
 employed for the reactions of I with primary amines, Dimroth
 rearrangements take place and the products are derivs. of 4-alkyl(or
 aryl)amino-5-alkyl(or aryl)imino-2-phenyl-5H-[1]benzopyrano[3,4-
 c]pyridine. The latter compds. are hydrolyzed by acid to the
 corresponding 5-pyridone derivs. The reactions of I with piperidine gives
 2-phenyl-4-piperidyl-5H-[1]benzopyrano[3,4-c]pyridin-5-one. NaOMe reacts
 with I to give 3-cyano-2-methoxy-4-(2-hydroxyphenyl)-6-phenylpyridine.
 Two benzologs of I were allowed to react with primary and secondary amines
 and the products are analogous to those obtained from I.
 IT **30155-82-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 30155-82-9 SCAPLUS
 CN Naphtho[2',1':5,6]pyrano[2,3,4-de]quinazoline-3-carbonitrile,
 2,5-diphenyl- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L14 ANSWER 3 OF 4 SCAPLUS COPYRIGHT 2009 ACS on SIN (Continued)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 12:25:19 ON 18 NOV 2009)

FILE 'ZCAPLUS' ENTERED AT 12:25:29 ON 18 NOV 2009

L1 1 US20070078132 /PN

FILE 'REGISTRY' ENTERED AT 12:25:40 ON 18 NOV 2009

FILE 'ZCAPLUS' ENTERED AT 12:25:41 ON 18 NOV 2009

L2 TRA L1 1- RN : 61 TERMS

FILE 'REGISTRY' ENTERED AT 12:25:41 ON 18 NOV 2009

L3 61 SEA L2

L4 STR

L5 16 L4

L6 54 L3 AND RSD/FA

L7 415 L4 FULL

SAV TEM J512C1/A L7

L8 23 L7 AND L3

L9 392 L7 NOT L8

FILE 'ZCAPLUS' ENTERED AT 12:40:42 ON 18 NOV 2009

L10 1 L8

L11 11 L9

L12 2 L11 AND (PRD<=20041215 OR AD<=20041215)

L13 2 L11 AND PD<=20031218

L14 4 L12-13

L15 7 L11 NOT L14

=>